RxDoctor Payments Data

Julia Short

Family · Palestine, TXNPI 1316510027

Payments from drug & device makers

$919in general payments, 2019–2025

Across 50 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$217
  • Lilly USA, LLC$168
  • Pfizer$158
  • Otsuka America Pharmaceutical, Inc.$85
  • Xeris Pharmaceuticals, Inc.$75
  • Biogen$59
  • plus $157 from 6 others

What the payments were for

  • Food & beverage$919100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$919 in reported general payments places this provider in the 65th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$45,739
Medicare patients
137
Services billed
915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$129,792
MounjaroTirzepatide85$102,402
RybelsusSemaglutide45$65,338
TrulicityDulaglutide39$54,560
JardianceEmpagliflozin45$47,282
EliquisApixaban53$42,139
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$26,638
Synjardy XrEmpagliflozin/Metformin Hcl33$25,341
JanuviaSitagliptin Phosphate20$22,697
MyrbetriqMirabegron30$16,480
Combivent RespimatIpratropium/Albuterol Sulfate27$14,386
SymbicortBudesonide/Formoterol Fumarate12$6,983
Gabapentin196$3,650
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$3,484
Albuterol Sulfate HfaAlbuterol Sulfate124$3,389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$217$195,131135 claims
Lilly USA, LLCMounjaro, Trulicity$168$156,962124 claims
PfizerEliquis$158$42,13953 claims
GSKTrelegy Ellipta$19$26,63837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 15,456 family providers in Texas.

Other family in Palestine

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →